DK2901341T3 - Identifikation af tumorbeskyttelsesepitoper til behandling af cancere - Google Patents
Identifikation af tumorbeskyttelsesepitoper til behandling af cancere Download PDFInfo
- Publication number
- DK2901341T3 DK2901341T3 DK13840946.1T DK13840946T DK2901341T3 DK 2901341 T3 DK2901341 T3 DK 2901341T3 DK 13840946 T DK13840946 T DK 13840946T DK 2901341 T3 DK2901341 T3 DK 2901341T3
- Authority
- DK
- Denmark
- Prior art keywords
- epitopes
- identification
- cancer treatment
- tumor protection
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Databases & Information Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707295P | 2012-09-28 | 2012-09-28 | |
| PCT/US2013/062100 WO2014052707A2 (en) | 2012-09-28 | 2013-09-27 | Identification of tumor-protective epitopes for the treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2901341T3 true DK2901341T3 (da) | 2019-07-15 |
Family
ID=50389139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13840946.1T DK2901341T3 (da) | 2012-09-28 | 2013-09-27 | Identifikation af tumorbeskyttelsesepitoper til behandling af cancere |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10501801B2 (da) |
| EP (1) | EP2901341B1 (da) |
| JP (2) | JP6501708B2 (da) |
| AU (2) | AU2013323368B2 (da) |
| DK (1) | DK2901341T3 (da) |
| ES (1) | ES2737757T3 (da) |
| HR (1) | HRP20191182T1 (da) |
| LT (1) | LT2901341T (da) |
| WO (1) | WO2014052707A2 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2901341T (lt) | 2012-09-28 | 2019-09-25 | The University Of Connecticut | Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui |
| EP3919070B1 (en) * | 2013-03-14 | 2024-10-16 | Children's Medical Center Corporation | Use of cd36 to identify cancer subjects for treatment by a psap peptide |
| WO2015153991A1 (en) * | 2014-04-04 | 2015-10-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Radiotherapy targeted to promote a systemic abscopal effect |
| US11338026B2 (en) | 2014-09-10 | 2022-05-24 | The University Of Connecticut | Identification of immunologically protective neo-epitopes for the treatment of cancers |
| JP2017528143A (ja) * | 2014-09-10 | 2017-09-28 | ザ ユニバーシティ オブ コネチカット | 癌の治療のための免疫防御ネオエピトープ同定 |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| CA3172682A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| KR20180006945A (ko) | 2015-05-13 | 2018-01-19 | 아게누스 인코포레이티드 | 암 치료 및 예방용 백신 |
| EP3302574A4 (en) * | 2015-05-26 | 2018-10-17 | Advaxis, Inc. | Personalized delivery vector-based immunotherapy and uses thereof |
| EP4407622A2 (en) * | 2015-07-14 | 2024-07-31 | Personal Genome Diagnostics Inc. | Neoantigen analysis |
| US20180237861A1 (en) * | 2015-08-13 | 2018-08-23 | Champions Oncology, Inc. | Personalized treatment of diseases and disorders |
| JP2018532736A (ja) | 2015-10-12 | 2018-11-08 | ナントミクス，エルエルシー | チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法 |
| AU2016339022B2 (en) | 2015-10-12 | 2020-09-10 | Nantomics, Llc | Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor |
| CN108495649A (zh) | 2016-01-08 | 2018-09-04 | 瓦西博迪公司 | 治疗性抗癌新表位疫苗 |
| JP6710004B2 (ja) * | 2016-03-15 | 2020-06-17 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計 |
| JP7197481B2 (ja) | 2016-11-30 | 2022-12-27 | アドバクシス， インコーポレイテッド | 反復性がん突然変異を標的とする免疫原性組成物およびその使用の方法 |
| US12072337B2 (en) | 2017-05-30 | 2024-08-27 | Nant Holdings Ip, Llc | Circulating tumor cell enrichment using neoepitopes |
| JP2021522239A (ja) | 2018-04-26 | 2021-08-30 | アジェナス インコーポレイテッド | 熱ショックタンパク質結合ペプチド組成物およびその使用方法 |
| US11920202B2 (en) | 2020-04-09 | 2024-03-05 | University Of Connecticut | Unbiased identification of tumor rejection mediating neoepitopes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1892306A3 (en) * | 2003-10-06 | 2008-06-11 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| US8140270B2 (en) | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| EP2569633B1 (en) * | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| DK2714071T3 (da) | 2011-05-24 | 2019-09-16 | Biontech Rna Pharmaceuticals Gmbh | Individualiserede vacciner mod cancer |
| LT2901341T (lt) | 2012-09-28 | 2019-09-25 | The University Of Connecticut | Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui |
-
2013
- 2013-09-27 LT LTEP13840946.1T patent/LT2901341T/lt unknown
- 2013-09-27 US US14/431,093 patent/US10501801B2/en active Active
- 2013-09-27 DK DK13840946.1T patent/DK2901341T3/da active
- 2013-09-27 EP EP13840946.1A patent/EP2901341B1/en not_active Not-in-force
- 2013-09-27 JP JP2015534719A patent/JP6501708B2/ja not_active Expired - Fee Related
- 2013-09-27 WO PCT/US2013/062100 patent/WO2014052707A2/en active Application Filing
- 2013-09-27 AU AU2013323368A patent/AU2013323368B2/en not_active Ceased
- 2013-09-27 ES ES13840946T patent/ES2737757T3/es active Active
-
2019
- 2019-01-10 JP JP2019002924A patent/JP2019058190A/ja active Pending
- 2019-06-20 AU AU2019204354A patent/AU2019204354A1/en not_active Abandoned
- 2019-07-01 HR HRP20191182TT patent/HRP20191182T1/hr unknown
- 2019-09-23 US US16/578,937 patent/US20200017922A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6501708B2 (ja) | 2019-04-17 |
| WO2014052707A3 (en) | 2015-05-14 |
| JP2015533082A (ja) | 2015-11-19 |
| WO2014052707A2 (en) | 2014-04-03 |
| US20150252427A1 (en) | 2015-09-10 |
| JP2019058190A (ja) | 2019-04-18 |
| LT2901341T (lt) | 2019-09-25 |
| ES2737757T3 (es) | 2020-01-15 |
| EP2901341A2 (en) | 2015-08-05 |
| US20200017922A1 (en) | 2020-01-16 |
| US10501801B2 (en) | 2019-12-10 |
| AU2019204354A1 (en) | 2019-07-11 |
| EP2901341B1 (en) | 2019-04-10 |
| AU2013323368B2 (en) | 2019-03-21 |
| HRP20191182T1 (hr) | 2019-10-04 |
| EP2901341A4 (en) | 2016-10-05 |
| AU2013323368A1 (en) | 2015-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2901341T3 (da) | Identifikation af tumorbeskyttelsesepitoper til behandling af cancere | |
| IL288181A (en) | Cancer treatment methods | |
| DK2897620T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3033086T3 (da) | Kombinationsterapi til behandling af cancer | |
| DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
| DK2818482T3 (da) | Farmaceutisk sammensætning til behandling af cancer | |
| DK2824114T3 (da) | Farmaceutisk sammensætning til behandling af cancer | |
| IL241232B (en) | Cancer treatment agents | |
| DK2900061T3 (da) | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling | |
| DK3046583T3 (da) | Viruslignende partikelkonjugater til behandling af tumorer | |
| EP2968348A4 (en) | COMPOUNDS FOR THE TREATMENT OF CANCER | |
| BR112014032105A2 (pt) | método para o tratamento de câncer | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK2785349T3 (da) | Kombinationsbehandling af cancer | |
| BR112014028424A2 (pt) | compostos de pirimidina para o tratamento de câncer | |
| DK3305285T3 (da) | Anti-androgener til behandlingen af ikke-metastatisk kastrationsresistent prostatakræft | |
| DK2825558T3 (da) | Kombinationsterapi til behandling af ovariecancer | |
| DK3511004T3 (da) | Kombineret præparat til behandling af cancer | |
| DK2892535T3 (da) | Fremgangsmåde til adjuverende cancerbehandling | |
| EP2903644A4 (en) | TREATMENT OF CANCER | |
| DK3077544T3 (da) | Rationelt-baseret design af en målrettet terapi til cancer | |
| DK3052102T3 (da) | Sammensætninger til behandling af cancere | |
| DK3290035T3 (da) | Procaspase-kombinationsterapi til behandling af cancer | |
| GB201217892D0 (en) | Treatment of cancer | |
| DK2802351T3 (da) | Midler til behandling af triple-negativ brystkræft |